Wat is de prijs voor Gilead Sciences, Inc. (GILD)

Het prijs van Gilead Sciences, Inc. (GILD) is $137.21

Wat is de marktkapitalisatie voor Gilead Sciences, Inc. (GILD)

Marktkapitalisatie voorGilead Sciences, Inc. (GILD) is $170.34B

Gilead Sciences, Inc. (GILD) Uitstaande Aandelen

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Jaar	Uitstaande aandelen	Wijzigen
2026 (TTM)	1.24B	-0.16%
2025	1.24B	-0.24%
2024	1.25B	-0.08%
2023	1.25B	-0.56%
2022	1.26B	-0.08%
2021	1.26B	-0.08%
2020	1.26B	-1.02%
2019	1.27B	-2.16%
2018	1.30B	-0.69%
2017	1.31B	-2.39%
2016	1.34B	-8.54%
2015	1.46B	-3.81%
2014	1.52B	-0.43%
2013	1.53B	0.92%
2012	1.51B	-2.27%
2011	1.55B	-9.48%
2010	1.71B	-5.37%
2009	1.81B	-1.75%
2008	1.84B	-0.91%
2007	1.86B	1.19%
2006	1.84B	1.05%
2005	1.82B	5.17%
2004	1.73B	7.41%
2003	1.61B	2.84%
2002	1.56B	2.78%
2001	1.52B	4.47%
2000	1.46B	0.00%

Jaar

Uitstaande aandelen

Wijzigen

2026 (TTM)

1.24B

-0.16%

2025

1.24B

-0.24%

2024

1.25B

-0.08%

2023

1.25B

-0.56%

2022

1.26B

-0.08%

2021

1.26B

-0.08%

2020

1.26B

-1.02%

2019

1.27B

-2.16%

2018

1.30B

-0.69%

2017

1.31B

-2.39%

2016

1.34B

-8.54%

2015

1.46B

-3.81%

2014

1.52B

-0.43%

2013

1.53B

0.92%

2012

1.51B

-2.27%

2011

1.55B

-9.48%

2010

1.71B

-5.37%

2009

1.81B

-1.75%

2008

1.84B

-0.91%

2007

1.86B

1.19%

2006

1.84B

1.05%

2005

1.82B

5.17%

2004

1.73B

7.41%

2003

1.61B

2.84%

2002

1.56B

2.78%

2001

1.52B

4.47%

2000

1.46B

0.00%

Bedrijf	Uitstaande aandelen	Verschil	Land
Eli Lilly LLY.US	898.00M	-27.70%	US
AstraZeneca PLC AZN.US	3.10B	149.60%	GB
Johnson & Johnson JNJ.US	2.43B	95.54%	US
AbbVie Inc. ABBV.US	1.78B	43.35%	US
Novartis AG NVS.US	1.91B	54.03%	CH

Bedrijf

Uitstaande aandelen

Verschil

Land